The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.
|Videos|April 2, 2022
AUPN Leadership Minute Episode 20: Putting the Burn on Burnout
Author(s)Rohit Das, MD, Cormac O'Donovan, MD
Episode 20 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and Cormac O'Donovan, MD, of Wake Forest Baptist. [WATCH TIME: 4 minutes]
Advertisement
WATCH TIME: 4 minutes
AUPN's Leadership Minute is a brief, highly focused summary of practical advice for Chairs, Program Directors and other leaders in academic neurology, available as both mini-podcasts and in short form videos.
The goal of this program is to provide relevant and useful information in a modicum of time, designed to fit seamlessly into our very busy schedules.
The Burnout Curve
Professional Fulfillment Index
- I feel HAPPY at work.
- I feel WORTHWHILE at work.
- My work is SATISFYING to me.
- I feel in CONTROL when dealing with difficult problems at work.
- My work is MEANINGFUL to me.
- I am contributing professionally in the ways I VALUE most.
The 4 S's
- STRUCTURE
- SOCIAL
- STIMULATION
- STORY
- Adding a 5th: SAFETY
Advertisement
Related to this article
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease
2
CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease
3
Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient
4
Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches
5